Upstream Bio Establishes $150M At-The-Market Equity Offering Program

summarizeSummary

Upstream Bio, a life sciences company, has established a new At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of common stock from time to time.

check_boxKey Events

• New At-The-Market (ATM) Program Established

  Upstream Bio entered into a Sales Agreement with Leerink Partners LLC to establish an At-The-Market (ATM) equity offering program.

• Significant Capital Raising Potential

  The company may offer and sell shares of common stock with an aggregate sales price of up to $150,000,000 through the ATM program.

• Potential Share Dilution

  Sales under the ATM program will be made from time to time, potentially increasing the number of outstanding shares and diluting existing shareholder value.

• Follows Shelf Registration

  This ATM offering is being made pursuant to the company's shelf registration statement on Form S-3ASR, which was filed on November 5, 2025, with a prospectus supplement filed today, March 26, 2026, finalizing the program's terms.

auto_awesomeAnalysis

Upstream Bio has established a substantial At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of common stock. While this program provides significant capital-raising flexibility for the life sciences company, it also introduces potential dilution for existing shareholders as shares are sold into the market over time. This financing mechanism is common for biotech firms to fund ongoing research and development, including planned Phase 3 trials, and extend their cash runway. The establishment of this program follows the company's recent annual report which detailed widened net losses but confirmed a strong cash position through 2027, indicating a proactive approach to securing long-term funding.